Best Biological Age Tests 2026: PhenoAge vs GrimAge vs DunedinPACE vs TruAge — A DAOM Comparison

Biological age tests measure how fast you’re aging vs. your chronological age. The four major epigenetic clocks in 2026 — PhenoAge, GrimAge, DunedinPACE, and TruDiagnostic TruAge — each answer a different question. DunedinPACE measures pace of aging; GrimAge predicts mortality; PhenoAge tracks physiological age; TruAge bundles multiple clocks plus organ-specific aging.

Why Biological Age Tests Matter In 2026

Chronological age tells you how many years you’ve been alive. Biological age tells you how fast your body has been aging. A 45-year-old patient can have a biological age of 38 (slow agers — typically with strong lifestyle, sleep, metabolic, and microbiome foundations) or a biological age of 53 (accelerated agers — typically with chronic stress, microclot biology, post-COVID amplification, or metabolic dysregulation).

In the executive cohort I see at the Newport Beach clinic — founders, fund managers, C-suite operators — the gap between chronological age and biological age is often the single most actionable longitudinal data point. A patient who’s outpacing their chronological age by 5–8 years has structural physiology to fix. A patient pacing well has a maintenance protocol to lock in.

This guide compares the four major biological age tests available in 2026, what each one actually measures, and where each one fits in a DAOM-led integrative protocol.

The Four Major Tests — Side-By-Side

What Each One Actually Tells You

PhenoAge — The Accessible Entry Point

Strengths:

• Built from standard blood biomarkers — most functional medicine labs include it automatically
• Validated extensively in epidemiology studies
• Useful as a baseline + tracking metric when run quarterly alongside standard labs

Limitations:

• Doesn’t capture epigenetic methylation patterns directly
• Less sensitive to short-term intervention changes than methylation-based clocks
• Doesn’t include the predictive-mortality framing of GrimAge

Clinical use: In my clinic, PhenoAge runs as part of every Executive Tier baseline panel. It’s the lowest-cost biological age data point, and tracking it quarterly catches drift early.

GrimAge — The Mortality-Prediction Clock

Strengths:

• Best-validated mortality and morbidity prediction tool in the epigenetic-clock category
• Sensitive to lifestyle interventions over 6–12 months
• Maps directly to specific aging hallmarks — smoking history, cardiovascular markers, metabolic stress, immune aging

Limitations:

• The “biological age” output is a mortality-predictor, not a pace-of-aging measure (different question than DunedinPACE)
• Cost gates accessibility for routine quarterly tracking
• Heavily influenced by historical smoking exposure

Clinical use: GrimAge is the Executive Tier specialty test I order most often for patients tracking long-term intervention effectiveness. The mortality-prediction lens resonates with the founder/fund-manager cohort.

DunedinPACE — The Pace-Of-Aging Clock

Strengths:

• Direct measure of how fast you’re aging right now (biological-years-per-chronological-year)
• Most sensitive to intervention changes over 6 months
• Built from the Dunedin Study cohort (~1,000 participants tracked since 1972) — extraordinary validation
• Single number output is easy to communicate clinically

Limitations:

• Less mortality-prediction power than GrimAge for static snapshots
• Requires DNA methylation testing
• Cost similar to GrimAge

Clinical use: DunedinPACE is my favorite intervention-tracking test. When a patient runs a 6-month Bright Post-GLP-1 Protocol or a 90-day CEO Cortisol Audit framework, DunedinPACE delta between baseline and 6-month re-test is the cleanest single number to show whether the protocol is moving the dial.

TruDiagnostic TruAge + TruHealth — The Comprehensive Bundle

Strengths:

• Bundles GrimAge + DunedinPACE + OMICmAge + 11 organ-specific aging clocks in a single test
• Eliminates the need to run multiple separate clocks
• TruHealth add-on adds methylation-based actionable insights
• Best total economics if you want multiple clocks at once

Limitations:

• Higher single-test cost than running one clock alone
• The 11 organ-specific clocks are newer — validation depth varies
• TruHealth reads methylation patterns for lifestyle factors (useful, but standard panels read the same at lower cost)

Clinical use: TruAge is the Comprehensive Executive Tier baseline test I order most often. The bundling is more cost-efficient than running tests separately, and the organ-specific outputs narrow protocol focus.

How These Tests Fit In A DAOM-Led Integrative Protocol

The biological age test is the measurement layer. The DAOM-led protocol is the intervention layer. Both matter, neither substitutes for the other.

In the Executive Tier of my clinic, biological age testing runs at three checkpoints:

Baseline (Q1 of Year 1): TruDiagnostic TruAge + TruHealth bundle as comprehensive baseline. PhenoAge captured automatically in standard biomarker panel.

6-month re-measure: DunedinPACE alone (lowest-cost re-test most sensitive to intervention changes).

12-month re-measure: Full TruAge re-test to capture GrimAge, DunedinPACE, organ-specific clocks. Year-over-year delta justifies continuing the protocol architecture.

Between checkpoints, the actual protocol — DAOM acupuncture, custom Chinese herbal formulas, supplements + peptide protocol management, CEO Cortisol Audit framework, sleep architecture optimization, autonomic regulation — does the work that moves the numbers.

What The Tests Can’t Tell You

1. Why your biological age is elevated. A 53-biological-age patient could be running accelerated aging from chronic stress, post-COVID microclot biology, MCAS amplification, perimenopausal hormonal shifts, metabolic syndrome, sleep architecture collapse, or all of the above. The test gives you the number; the clinical workup gives you the why.

2. Which intervention will move your number most. The number itself is intervention-agnostic. The DAOM + Functional Medicine clinical assessment maps your specific picture to the highest-leverage interventions.

3. The TCM pattern underneath. Western biological-age clocks don’t read tongue, pulse, or channel theory. The TCM pattern layer adds individualization that the clocks structurally cannot.

This is why biological age testing without integrative clinical interpretation is largely consumer entertainment. The number matters when it lives inside a clinical relationship that translates it into protocol.

Common Mistakes Patients Make With Biological Age Testing

1. Treating the number as a verdict. Biological age is movable. Patients running 90-day integrative protocols routinely see 0.05–0.15 DunedinPACE improvement.
2. Running the test once and not re-measuring. The intervention story shows up in the delta, not the baseline number.
3. Picking the cheapest test for the question they’re actually asking. PhenoAge is great for accessible screening; it doesn’t substitute for GrimAge’s mortality-prediction or DunedinPACE’s intervention-sensitivity.
4. Comparing across test methodologies. A PhenoAge of 38 and a GrimAge of 38 measure different things. Don’t average them.
5. Skipping the clinical interpretation. The number is the data; the protocol is the work.

Frequently Asked Questions

Conclusion

Biological age testing in 2026 is the highest-resolution longevity data point available outside of research labs. PhenoAge is the accessible entry point. GrimAge is the mortality-prediction clock. DunedinPACE is the intervention-tracking clock. TruDiagnostic TruAge bundles them efficiently for comprehensive workups. None of them substitute for clinical interpretation — that’s where DAOM-led integrative care turns the number into a protocol.

If you want to map your specific biological age picture to a clinical intervention plan, the 15-minute Executive Tier discovery call is the starting point.

Disclaimer: Educational content. Not medical advice. Dr. Brandon Bright is a DAOM, LAc — not a medical doctor. Biological age testing is a measurement tool; clinical interpretation and intervention design require integrative clinical assessment. Test costs and methodology details based on public marketing through May 2026; confirm directly with each lab. The clinic is cash-pay / direct specialty care and not in-network.